Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms

Myeloproliferative Neoplasms (B Stein, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Myeloproliferative Neoplasms

Abstract

Purpose of Review

The purpose of this article is to review the current evidence behind interferon therapy in patients with myeloproliferative neoplasms.

Recent Findings

Preliminary analysis suggests that interferon may be non-inferior to hydroxyurea in patients with polycythemia vera and essential thrombocytosis. Responses have been observed regardless of JAK2 mutational status, but the presence of non-JAK2 somatic mutations may negatively influence response rates.

Summary

Pegylated interferon has proven efficacy for patients with myeloproliferative neoplasms. Both newly diagnosed and previously treated patients with polycythemia vera and essential thrombocytosis exhibit high hematologic response rates, and some of these patients achieve molecular responses as well. Interferon therapy leads to lower rates of hematologic response in MF patients, but patients earlier on in their disease course have a better chance of responding. There are ongoing trials comparing pegylated interferon to hydroxyurea in essential thrombocytosis (ET) and polycythemia vera (PV), and early analysis suggests non-inferiority. However, longer follow-up is needed before drawing any conclusions. Future research is needed to better define characteristics of the best responders and to determine whether novel forms of interferon therapy or combination therapy with interferon can enhance efficacy and tolerability.

Keywords

Polycythemia vera Essential thrombocytosis Primary myelofibrosis Interferon 

References

  1. 1.
    Bellucci S, Harousseau JL, Brice P, Tobelem G. Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet. 1988;2(8617):960–1.CrossRefPubMedGoogle Scholar
  2. 2.
    Silver RT. Recombinant interferon-alpha for treatment of polycythemia vera. Lancet. 1988;2(8607):403.CrossRefPubMedGoogle Scholar
  3. 3.
    Kiladjian J-J, Giraudier S, Cassinat B. Interferon-alpha for the therapy of meloproliferative neoplasms: targeting the malignant clone. Leukemia. 2016;30:776–81.CrossRefPubMedGoogle Scholar
  4. 4.
    Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, et al. Myelodysplastic syndromes, version 2.2017: clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(1):28.Google Scholar
  5. 5.
    Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–70.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kiladjian J-J, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065–72.CrossRefPubMedGoogle Scholar
  7. 7.
    Turlure P, Cambier N, Rouseel M, Bellucci S, Zini J-M, Rain J-D, et al. Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon α-2a (peg-INFα-2a) therapy in polycythemia vera (PV): Long term results of a Phase 2 trial. Proc ASH. 2011; abstract 280.Google Scholar
  8. 8.
    Silver RT. Long-term effects of the treatment of polycythemia Vera with recombinant interferon-α. Cancer. 2006;107(3):451–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418–24.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Quintas-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie A-L, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013;122(6):893–901.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Masarova L, Verstovsek S, Patel KP, Newberry KJ, Cortes JE, Borthakur G, et al. Efficacy and safety of pegylated interferon alpha-2a in patients with essential Thrombocythemia and polycythemia vera: results after a median 7-year follow-up of a phase 2 study. Blood. 2015:126(60).Google Scholar
  12. 12.
    Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762–8. This study prospectively studied a novel formulation of interferon, ropeginterferon, that requires less frequent dosing than currently available formulations of interferon. This formulation appeared to have similar efficacy in terms of hematologic and molecular response and had similar rates of toxicity compared to those of other formulations of pegylated interferon. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Gisslinger H, Klade C, Georgiev P, Skotnicki A, Gercheva-Kyuchukova L, Egyed M, et al. Final results from PROUD-PV a randomized controlled phase 3 trial comparing ropeginterferon alfa-2b to hydroxyurea in polycythemia vera patients. Proc ASH. 2016. Abstract 475.Google Scholar
  14. 14.
    Mascarenhas JO, Prchal JT, Rambaldi A, Mesa RA, Berenzon D, Yacoub A, et al. Interim analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 global phase III trial of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia. Proc ASH. 2016. Abstract 479.Google Scholar
  15. 15.
    Mesa RA, Hoffman R, Kosiorek HE, Prchal JT, Harrison CN, McMullin MF, et al. Impact on MPN symptoms and quality of life of front line pegylated alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia: interim analysis results of Myeloproliferative Disorders Consortium (MPD-RC) 112 global phase III trial. Proc ASH. 2016. Abstract 4271.Google Scholar
  16. 16.
    Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter M-H, et al. Clinical and molecular response to interferon alpha therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015;126(24):2585–91. This study looks specifically at interferon therapy in MPN patients with another driver mutation besides JAK2 V617F. CALR -mutated ET patients treated with interferon therapy achieved both hematologic and molecular responses. Additional abnormalities in the extended molecular profile appeared to negatively impact response to therapy, consistent with studies in patients with other driver mutations. CrossRefPubMedGoogle Scholar
  17. 17.
    Larsen TS, Moller MB, Stricker KD, Norgaard P, Samelsson J, Marcher C, et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patters in seven patients in sustained complete hematological remission. Hematology. 2009;14(6):331–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Rank CU, Bjerrum OW, Larsen TS, Kjaer L, Stricker KD, Riley CH, et al. Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma. 2016;57(2):1–7.Google Scholar
  19. 19.
    Gowin K, Thapaliya P, Sameulson J, Harrison C, Radia D, Andreasson B, et al. Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica. 2012;97(10):1570–3.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gowin K, Jain T, Kosiorek H, Tibes R, Camoriano J, Palmer J, et al. Pegylated interferon alpha-2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. Leuk Res. 2017;52:73–7.CrossRefGoogle Scholar
  21. 21.
    Larsen TS, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res. 2013;37:1041–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Silver RT, Vandris K, Goldman JJ. Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011;117(24):6669–72.CrossRefPubMedGoogle Scholar
  23. 23.
    Silver RT, Barel AC, Lascu E, Ritchie EK, Roboz GJ, Christos PJ, et al. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis. Cancer. 2017;123(14):2680–2687. Prospective trial investigating recombinant interferon-α in early myelofibrosis patients showed that driver mutation status did not affect response to therapy. However, both high molecular risk mutations and enlarged spleen at the initiation of therapy appeared to negatively affect response to interferon therapy. Google Scholar
  24. 24.
    Ianotto J-C, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory J-L. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol. 2013;162:783–91.CrossRefPubMedGoogle Scholar
  25. 25.
    O’Neill C, Siddiqi I, Brynes RK, Vergara-Lluri M, Moschiano E, O’Connell C. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy. Ann Hematol. 2016;95:733–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Mikkelsen SU, KJaer L, Skov V, Bjorn ME, Andersen CL, Bjerrum OW, et al. Safety and efficacy of combination therapy of interferon-alpha2 + JAK1–2 inhibitor in the philadelphia-negative chronic myeloproliferative neoplasms. Preliminary results from the danish combi-trial—an open label, single arm, non-randomized multicenter phase ii study. Proc ASH. 2015. Abstract 824.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Department of MedicineNorthwestern University Feinberg School of MedicineChicagoUSA
  2. 2.Department of Medicine, Division of Hematology/OncologyNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations